Plasmodium falciparum histidine-rich protein 1 associates with the band 3 binding domain of ankyrin in the infected red cell membrane  by Magowan, Cathleen et al.
Plasmodium falciparum histidine-rich protein 1 associates with the band 3
binding domain of ankyrin in the infected red cell membrane
Cathleen Magowan a;1, Wataru Nunomura b, Karena L. Waller d, Jackson Yeung a,
Joy Liang a;2, Heidi Van Dort c;3, Philip S. Low c, Ross L. Coppel d,
Narla Mohandas a;*
a Lawrence Berkeley National Laboratory Life Sciences Division, One Cyclotron Road, MS 157, Berkeley, CA 94720, USA
b Tokyo Women’s Medical University, Department of Biochemistry, Shinjuku, Tokyo 162-8666, Japan
c Purdue University, Department of Chemistry, West Lafayette, IN 47907, USA
d Monash University, Department of Microbiology, Clayton, Victoria, 3168, Australia
Received 17 December 1998; received in revised form 27 July 2000; accepted 10 August 2000
Abstract
Infection of erythrocytes by the malaria parasite Plasmodium falciparum results in the export of several parasite proteins
into the erythrocyte cytoplasm. Changes occur in the infected erythrocyte due to altered phosphorylation of proteins and to
novel interactions between host and parasite proteins, particularly at the membrane skeleton. In erythrocytes, the spectrin
based red cell membrane skeleton is linked to the erythrocyte plasma membrane through interactions of ankyrin with spectrin
and band 3. Here we report an association between the P. falciparum histidine-rich protein (PfHRP1) and phosphorylated
proteolytic fragments of red cell ankyrin. Immunochemical, biochemical and biophysical studies indicate that the 89 kDa
band 3 binding domain and the 62 kDa spectrin-binding domain of ankyrin are co-precipitated by mAb 89 against PfHRP1,
and that native and recombinant ankyrin fragments bind to the 5P repeat region of PfHRP1. PfHRP1 is responsible for
anchoring the parasite cytoadherence ligand to the erythrocyte membrane skeleton, and this additional interaction with
ankyrin would strengthen the ability of PfEMP1 to resist shear stress. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Infection with Plasmodium falciparum is one of the
leading causes of death worldwide. Over 500 million
people are infected each year resulting in 2^3 million
deaths annually. The asexual form of the parasite
living within the red blood cell is responsible for
the pathology and resulting morbidity and mortality
associated with infection. Changes in membrane
properties of infected red cells are secondary to the
insertion of parasite proteins into the red cell mem-
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brane and through interaction of parasite proteins
with red cell membrane proteins. Parasite proteins
participate in a number of protein^protein interac-
tions, both with proteins of the host red cell and
with other parasite proteins. Interactions that have
been mapped include those of the parasite protein
MESA with protein 4.1 [1], of RESA with spectrin
[2], of PfHRP1 with PfEMP1 [3], and of PfEMP1
with actin and spectrin [4].
One of the key processes involved in parasite vir-
ulence is sequestration, in which red cells containing
mature parasites bind to receptors on endothelial
cells of the deep vasculature. Receptors include
CD36, ICAM-1, and thrombospondin [5]. The para-
site ligand involved is PfEMP1 (P. falciparum eryth-
rocyte membrane protein 1), a transmembrane pro-
tein with a 45 kDa cytoplasmic domain that mediates
its interaction with the infected red cell membrane
skeleton [5,6]. PfEMP1 has been localized to speci¢c
sites on the infected red cell surface, overlying a
number of parasite-induced structures called knobs
[7]. Knobs are electron-dense membrane protrusions
with a diameter of V100 nm that are present in
about 5000 copies per infected cell [8,9]. One of the
major components of the knob is the knob associ-
ated histidine rich protein (KAHRP or PfHRP1), an
80^108 kDa parasite protein with extensive repeat
and histidine-rich regions. Several host proteins can
be found in puri¢ed knobs [10,11], and among these,
PfHRP1 has been shown to bind to spectrin and
actin [12], as has PfEMP1 [4]. Thus the cytoplasmic
domain of PfEMP1 binds to the spectrin-actin junc-
tion [4] and to PfHRP1 [3], which in turn binds to
host red cell membrane skeletal proteins to anchor
PfEMP1 to the membrane skeleton of the infected
red cell. This anchoring is crucial to parasite viru-
lence, and in parasites from which PfHRP1 is miss-
ing, PfEMP1 mediated binding is either completely
absent [13] or is decreased such that it is unable to
occur under £ow conditions equivalent to those
found in vivo [14].
Another important alteration in the infected red
cell is in the levels of phosphorylation of host red
cell proteins, as well as the appearance of parasite
phosphoproteins at the red cell membrane skeleton
[1,15^17]. These induced changes in protein phos-
phorylation may modulate the membrane mechanical
properties of the infected red cell [18]. MESA (the
mature-parasite-infected red cell surface antigen, also
called PfEMP2) is a phosphoprotein of parasite ori-
gin that is exported to the red cell membrane skele-
ton where it binds to protein 4.1 [1,16,19]. We have
recently shown that the presence of knobs and thus
the expression of PfHRP1 can in£uence phosphory-
lation of protein 4.1 and MESA, and/or expression
of the kinase(s) for which these proteins are sub-
strates in infected red cells [20].
In the present study, we detected a red cell phos-
phoprotein of V89 kDa in infected cells. This pro-
tein is clearly distinct from protein 4.1. Our studies
indicate that this protein is the 89 kDa Band 3 bind-
ing domain of ankyrin which is phosphorylated in
infected red cells, and that it is involved in non-co-
valent interaction with the P. falciparum knob pro-
tein PfHRP1. This is the ¢rst report of an association
between erythrocyte ankyrin and PfHRP1.
2. Materials and methods
2.1. Parasites
K+ Malayan Camp parasites [10], as well as three
K+ and K3 paired parasite lines were used in these
experiments. K+ D10 and K3 E12 were derived
from the FC-27 isolate [21]. K+ D63 and K3 D65
were derived from the D6 clone [22^24]. K+ P37 [24]
and K3 B8B6 [25] were derived from the ItG2F6
clone. Infected red cells were cultured at 2% hemat-
ocrit in RPMI 1640 supplemented with 10% human
serum or 0.5% Albumax II as previously described
[26]. Knob phenotype was con¢rmed by indirect im-
muno£uorescence as previously described [19] and, in
some cases, by electron microscopy (B.M. Cooke,
Monash University, Australia, personal communica-
tion).
2.2. Protein 4.1-de¢cient erythrocytes
Protein 4.1-de¢cient red cells, obtained with in-
formed consent from two di¡erent donors, have
been described previously [16,19,27]. The red cells
were washed, cryopreserved and thawed when
needed as previously described [19].
BBADIS 61983 25-10-00
C. Magowan et al. / Biochimica et Biophysica Acta 1502 (2000) 461^470462
2.3. Preparation of ankyrin
Human erythrocyte ankyrin and its fragments, the
89 kDa band 3 binding domain, its 43 kDa subfrag-
ment, and the 62 kDa spectrin binding domain, were
prepared as previously described [28,29].
2.4. Antibodies
Mouse monoclonal antibodies (mAbs) to MESA
(mAb Pf8b4.7) and to PfHRP1 (mAb 89) were
kindly provided by Drs Je¡rey Lyon (Walter Reed
Army Institute of Research, Washington, DC) and
Diane Taylor (Georgetown University, Washington,
DC) and have been previously described [30,31].
Antibody to protein 4.1 has been previously de-
scribed [20].
Antibodies to human heat shock proteins (hsp) 84
and 86 were kindly provided by Dr Shyamala Harris
(Lawrence Berkeley National Laboratory, Berkeley,
CA). Antibody to P. falciparum hsp 70 was gener-
ated against a recombinant protein expressing the C-
terminal half of the protein [32]. Antibodies to spec-
trin and protein kinase C were purchased from Sig-
ma Chemical Co. (St. Louis, MO). A⁄nity puri¢ed
rabbit antibody to the band 3 binding domain of
human ankyrin (termed ‘anti-ANK’ in this paper)
was prepared at Purdue University. For use in
some experiments, the anti-ANK antibody was ab-
sorbed three times on ice and once overnight with
inside-out-vesicles that were prepared from normal
human red blood cells as previously described [33].
The resulting antibody was reacted with infected and
uninfected red blood cells in indirect immuno£uores-
cence, as previously described [19], and immunopre-
cipitation analyses to determine whether the anti-
body’s activity was against erythrocyte ankyrin or a
parasite protein.
2.5. Preparations of recombinant proteins
All recombinant proteins were expressed in Esche-
richia coli [34,35]. The full-length PfHRP1 (second
exon) was ampli¢ed by PCR from genomic P. falci-
parum D10 DNA, cloned into the pMAL-c2 vector
(New England BioLabs, Beverly, MA), and ex-
pressed as a fusion of maltose binding protein. Re-
combinant PfHRP1 fragments [3] were produced as
glutathione S-transferase (GST) fusion proteins. The
minigenes were constructed in pGEX-KG vector.
The expression and puri¢cation of GST fusion pro-
teins has been described previously [34,35]. The re-
combinant 43 kDa fragment of ankyrin was cloned
into pGEMEX vector (a kind gift from Vann Ben-
nett, Duke University) that has been previously de-
scribed [28]. The 43 kDa fragment of ankyrin was
puri¢ed from a bacteria lysate as previously reported
[36,37]. The purity of the recombinant proteins was
assessed by analysis with sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE,
15% gel). The protein concentration was determined
as previously reported [34,35].
2.6. Binding assay by resonant mirror detection
Protein^protein interactions were studied using the
resonant mirror detection method [38,39] of the
IAsys system (A⁄nity Sensors, Cambridge, UK).
The immobilization of proteins to the aminosilane
cuvette has been previously described [34,35]. All
the binding assays were carried out in phosphate-
bu¡ered saline (PBS/T: 10 mM Na2HPO4/NaH2PO4
(pH 7.4), containing 0.15 M NaCl and 0.05% Tween-
20) at 25‡C under constant stirring.
The dissociation constant (termed KDkin) was
then calculated as KDkin = kd/ka, where ka is the as-
sociation rate constant, and kd is the dissociation
rate constant [34,35]. The cuvettes were reused after
cleaning with HCl. Original binding curves could
be replicated after HCl washes, implying that the
washing procedure did not denature the bound li-
gands.
2.7. Phosphorylation of infected and uninfected
erythrocytes
Infected and uninfected red cells were labeled as
previously described [20]. Brie£y, infected red cells
were incubated for 4^8 h with 250 WCi ml31 32PO4
in glutamine- and phosphate-free MEM supple-
mented with 10% human serum dialyzed against
0.15 M NaCl. Because membrane proteins in unin-
fected red cells are not heavily phosphorylated [1,16],
uninfected red cells were incubated with 4-L-phorbol
12-myristate (PMA, Sigma) at 40% hematocrit in the
presence of 1 mCi 32PO4 to maximize phosphoryla-
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tion of various red cell membrane proteins as previ-
ously described [20].
2.8. Biosynthetic labeling
[3H]Histidine and [3H]amino acid mixture were ob-
tained from Amersham (Arlington Heights, IL).
[35S]Methionine (Express protein labeling mix) was
obtained from NEN Research Products (Boston,
MA). Isotopes were added at 250 WCi ml31 to
RPMI 1640 Select-Amine media de¢cient in the ap-
propriate amino acid(s) (Gibco BRL, Gaithersburg,
MD). Parasites were cultured from ring stage to
trophozoites and immediately extracted for immuno-
precipitation at a ratio of 2.5U108 infected red cells
ml31 of extraction bu¡er.
2.9. Immunoprecipitation, SDS^PAGE and Western
blot analysis
These analyses were carried out as previously de-
scribed [20]. The Triton X-100-insoluble fraction of
protein 4.1-de¢cient human red cell lysates, or in-
fected red cell lysates, was extracted in 1% SDS to
extract non-ionic proteins. For immunoprecipitation,
excess Triton X-100 was added before addition of
antibody to avoid denaturation by SDS of the anti-
body [10,23,40,41]. Cellular extracts were precleared
with Protein A sepharose beads before the addition
of antibody, and 0.35 M NaCl was included in one
of the washes of immunoprecipitated Protein A
beads to reduce non-speci¢c binding. For Western
blots, extracts were directly loaded on 15% SDS^
polyacrylamide gels (PAGE). Equal amounts of in-
fected red cell extract were loaded in each experi-
ment. Proteins were separated by SDS^PAGE and
either autoradiographed or transferred to nitrocellu-
lose for Western blots. Blots were probed with anti-
body and reactions were visualized by chemilumines-
cence using the Renaissance system (Dupont NEN,
Boston, MA).
3. Results
3.1. Two V89 kDa phosphoproteins are detected in
infected erythrocytes
P. falciparum-infected red cells were cultured in the
presence of [32P]orthophosphate which results in la-
beling of phosphoproteins of both host and parasite
origin. A 32P-labeled band of V89 kDa was detected
in Triton X-100-insoluble extracts of normal red
blood cells infected with various cloned parasite
lines. As in previous studies, both polyclonal and
monoclonal antibody to MESA (Mrs 250 kDa) co-
precipitated this phosphoprotein from K+ and K3
infected red blood cells [1,20]. That this phosphopro-
tein is protein 4.1 has previously been shown by one-
and two-dimensional peptide mapping and by immu-
noprecipitation with an antibody speci¢c to protein
4.1 [1,16,20,42].
A 32P-labeled band with similar apparent mobility
was detected in Triton X-100-insoluble extracts of
protein 4.1-de¢cient infected red cells, indicating
that in addition to protein 4.1 there was a second
Table 1
PfHRP1 binding to ankyrin
Ankyrin PfHRP1a ka (M31 s31) kd (s31) KDkin (WM)
Band 3 binding domain
89 kDa Full length 7.0 þ 0.1U103 1.3 þ 0.1U1032 1.8
K2A 6.8 þ 0.3U103 1.6 þ 0.1U1032 2.4
43 kDa Full length 1.5 þ 0.1U104 2.0 þ 0.3U1032 1.3
K2A 2.2 þ 0.2U104 6.7 þ 0.3U1032 3.0
Spectrin binding domain
62 kDa Full length 2.9 þ 0.1U103 1.4 þ 0.2U1032 4.8
K2A 3.5 þ 0.1U103 2.9 þ 0.2U1032 8.3
The binding assay was carried out in PBS containing 0.05% Tween-20. From the binding curves obtained by the resonant mirror de-
tection method, ka, kd, and KDkin were determined using the software package FAST-¢t.
aFull-length PfHRP1, and the K2A region of this parasite protein, bind to fragments of human erythrocyte ankyrin.
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phosphoprotein of V89 kDa present in infected red
cells (Fig. 1a). This second phosphoprotein was de-
tected in infected protein 4.1-de¢cient red blood cells
from two di¡erent donors [16,19,27]. As expected,
antibodies directed to protein 4.1 failed to recognize
an antigen from these mutant red cells in the 89 kDa
region by Western blot or by immunoprecipitation.
Moreover, anti-MESA antibodies did not coprecipi-
tate this band from protein 4.1-de¢cient cells. Thus,
this second 89 kDa phosphoprotein does not possess
the immunochemical properties of protein 4.1, and is
not associated with MESA.
3.2. Novel phosphoprotein is recognized by mAb to
PfHRP1
Based on the size and detergent solubility proper-
ties of this phosphoprotein, we suspected it might be
PfHRP1, although PfHRP1 has not previously been
reported to be a phosphoprotein. mAb 89 against
parasite PfHRP1 immunoprecipitated an V89 kDa
phosphorylated protein from extracts of several K+
parasites but not from extracts of K3 parasites (Fig.
1b). On the other hand, anti-MESA antibody, which
has been shown to coprecipitate protein 4.1, immu-
noprecipitated an 89 kDa phosphoprotein from Tri-
ton X-100-insoluble extracts of both K+ and K3
parasites (Fig. 1b).
PfHRP1 is a protein that varies in size in di¡erent
isolates due to di¡erences in the number of repeats
within the protein [43]. When immunoprecipitation
studies using mAb 89 were performed with
[3H]histidine biosynthetically labeled parasite ex-
tracts and 32P-labeled infected red cell extracts of
the same lines, the precipitated phosphoprotein did
not show the same pattern of variation in size seen
with the biosynthetically labeled PfHRP1. Instead it
was found to be constant in size (V89 kDa) in all
Fig. 1. (a) Autoradiographs of SDS^PAGE gels of Triton X-100-insoluble extracts of 32P-labeled infected normal red blood cells (lane
A) and infected protein 4.1-de¢cient red blood cells (lane B). Extracts from equal amounts of red cells were loaded in each lane. A
phosphoprotein that migrates at a Mr similar to protein 4.1 (V89 kDa) is present in protein 4.1-de¢cient red cells (arrows). (b) Auto-
radiograph of SDS^PAGE gels of Triton X-100-insoluble extracts of 32P-labeled red cells infected with K+ parasite line FC27/D10 im-
munoprecipitated with anti-PfHRP1 mAb 89 (lane A) or anti-MESA antibody (lane B). Triton X-100 extracts of 32P-labeled red cells
infected with K3 parasite line FC27/E12 immunoprecipitated with anti-PfHRP1 mAb 89 (lane C) or anti-MESA antibody (lane D).
Extracts from equal amounts of red cells were loaded in each lane. Note that mAb 89 did not coprecipitate the second phosphopro-
tein in K3 infected red cells (lanes A compared with C), whereas anti-MESA antibody coprecipitated protein 4.1 in both K+ and
K3 infected cells (lanes B compared with D).
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isolates examined (Fig. 2). Thus, the 89 kDa protein
is a phosphoprotein that is co-precipitated with
PfHRP1 by mAb 89 and thus presumably binds to
PfHRP1 in both normal and protein 4.1-de¢cient
infected red blood cells.
3.3. Antibody to 43 kDa ankyrin fragment
immunoprecipitates the V89 kDa phosphoprotein
Antibodies against several proteins in this molec-
ular mass range of both malarial and host origin
were used for immunoprecipitation and Western
blot analysis. Antibodies directed against protein ki-
nase C, P. falciparum hsp 70, human hsp 84 and 86,
and spectrin failed to recognize a phosphoprotein of
V89 kDa in Triton X-100-insoluble extracts. How-
ever, anti-ANK antibody against the ankyrin repeats
13^24 (subdomains 3 and 4) of the 89 kDa band 3
binding domain immunoprecipitated a phosphopro-
tein which comigrated with both protein 4.1 and the
protein immunoprecipitated by mAb 89 (Fig. 3). The
intensity of phosphorylation of the polypeptide rec-
ognized by anti-ANK is not as strong as the intensity
of phosphorylation of the polypeptide coprecipitated
by anti-PfHRP1. This might result from increased
phosphorylation of the ankyrin fragment in associa-
tion with PfHRP1, or an increased association of
PfHRP1 with a subpopulation of more heavily phos-
phorylated ankyrin fragments.
3.4. Novel phosphoprotein is of red cell origin
To determine whether the anti-ANK antibody was
reacting with red cell ankyrin or a malarial ankyrin-
like protein [44], e¡orts were made to biosyntheti-
cally label the protein. [3H]histidine, [3H]amino acid
mixture and [35S]methionine failed to label a protein
in the 89 kDa region that was immunoprecipitated
by anti-ANK antibody in either K+ or K3 infected
red cells. Further evidence that the phosphoprotein is
of red cell origin was provided by absorbing anti-
ANK antibody with inside-out vesicles generated
from uninfected red cells and showing that this
depleted antibody failed to recognize the phospho-
protein in infected red cell extracts by immunopreci-
pitation, and did not react by indirect immuno£uo-
rescence with the membranes of either infected or
uninfected red blood cells. Taken together, these
data o¡er evidence that the phosphoprotein we iden-
ti¢ed is of red cell origin.
3.5. Biophysical assays demonstrate binding of
ankyrin and PfHRP1
We went on to examine the PfHRP1-ankyrin frag-
ment binding in detail. To do this, we generated full-
length PfHRP1, and a number of puri¢ed native and
recombinant fragments of PfHRP1 and ankyrin. The
IAsys system was used to determine the a⁄nity of
binding between these proteins. Binding studies of
full-length and various regions of PfHRP1, and the
89 kDa fragment of ankyrin, indicated that the 89
kDa ankyrin fragment bound speci¢cally with the 5P
repeat region of PfHRP1, region K2A. Deletion of
the 5P repeat region K2 [3] resulted in loss of binding
(data not shown). Similar results were obtained using
the smaller recombinant 43 kDa subfragment of an-
kyrin instead of the 89 kDa ankyrin fragment. Table
1 shows the KDkin values of full-length PfHRP1 and
the K2A region, and the fragments of ankyrin. The
KDkin of binding between full-length PfHRP1 and
the 89 kDa and the 43 kDa ankyrin fragments were
1.8 and 1.3 WM, respectively. The KDkin of binding
between the PfHRP1 region K2A and the 89 kDa
and 43 kDa fragments were 2.4 and 3.0 WM, respec-
tively. Both the association rate constant (ka) and
the dissociation rate constant (kd) of K2A binding
with the 43 kDa ankyrin fragment were about three
Fig. 2. Autoradiograph of SDS^PAGE gels of Triton X-100-in-
soluble extracts immunoprecipitated with anti-PfHRP1 mAb 89.
Compare the migration of [3H]histidine biosynthetically labeled
parasite lines D63 (lane A) and Malayan Camp (lane B) with
32P-labeled phosphoprotein in D63 (lane C) and Malayan
Camp (lane D). Note the size polymorphism of PfHRP1 in
lanes A and B, and the lack thereof for the second phospho-
protein in lanes C and D. Extracts from equal amounts of red
cells were loaded in each lane.
BBADIS 61983 25-10-00
C. Magowan et al. / Biochimica et Biophysica Acta 1502 (2000) 461^470466
times higher than K2A binding with the 89 kDa frag-
ment.
A second phosphoprotein that shared the bio-
chemical characteristics of the 89 kDa fragment
was also coprecipitated by anti-PfHRP1 mAb 89
(Fig. 1b, lane A and Fig. 3, lane C). We suspected
this might be the 62 kDa spectrin binding domain of
ankyrin. Therefore, we also examined binding of this
domain, derived from native ankyrin, to PfHRP1.
The 62 kDa fragment also speci¢cally bound to
PfHRP1 region K2A with a KDkin of 8.3 WM, and
to full-length PfHRP1 with a KDkin of 4.8 WM (Ta-
ble 1). These experiments used native or recombinant
fragments of ankyrin that were not phosphorylated.
The repeat region of PfHRP1 K2A contains several
basic amino acid clusters (e.g., KKKKSKKHK), and
it may be that phosphorylated ankyrin fragments
would bind to the K2A region with higher a⁄nity.
4. Discussion
In the present study, we have shown that two
phosphorylated proteins of V89 kDa are present
in P. falciparum-infected red cells. As previously
documented, one of these proteins is red cell protein
4.1, which is more heavily phosphorylated in infected
red cells compared to uninfected red cells and is
bound by the parasite protein MESA. The second
phosphorylated protein, identi¢ed in the present
study in both normal and 4.1-de¢cient red cells, is
the 89 kDa band 3 binding domain of ankyrin. It
was coprecipitated by anti-PfHRP1 antibody but
not by anti-MESA antibodies. It was detected by
anti-ANK antibody in both K+ and K3 infected
red cells but was coprecipitated by antibody against
PfHRP1 only from K+ infected red blood cells, sug-
gesting a non-covalent association with PfHRP1.
Although red cells contain about 200 000 copies of
ankyrin, as few as 5000 knobs are induced on the
infected red cell membrane. The number of copies
of PfHRP1 per knob is unknown, as is the fraction
of ankyrin that is associated with PfHRP1. However,
a phosphorylated fragment of ankyrin, even in low
abundance, might signi¢cantly alter properties of the
infected red cell membrane, particularly locally at the
knob. Possible e¡ects include changes in the adhesive
properties of the erythrocyte through activation of
cryptic red cell adhesion proteins that are themselves
present in only a few thousand copies per cell. Modi-
¢ed band 3 has been suggested to be a cytoadherence
ligand in infected cells [40]. Whether phosphorylation
and binding of the band 3 binding domain of ankyr-
in to PfHRP1 leads to changes in the distribution
and/or mobility of band 3 that would a¡ect cytoad-
herence remains to be elucidated.
A 62 kDa phosphoprotein that shared the bio-
chemical and immunochemical characteristics of the
89 kDa ankyrin fragment was also coprecipitated by
anti-PfHRP1 antibodies. Data from our in vitro
binding studies con¢rm that both the 89 kDa band
3 binding domain and the 62 kDa spectrin binding
domain of ankyrin bind speci¢cally to the K2A re-
gion of PfHRP1. Thus the 62 kDa spectrin binding
domain of ankyrin appears to be an additional bind-
ing site on the ankyrin molecule for PfHRP1, which
has also been shown to bind to spectrin and actin
[12].
Ankyrins constitute a family of proteins that ap-
pear to serve a general role in coupling diverse inte-
gral proteins to the spectrin^actin network [45]. Er-
ythrocyte ankyrin is a structural protein that links
Fig. 3. Autoradiograph of SDS^PAGE gels of Triton X-100-in-
soluble extracts of 32P-labeled red cells infected with K+ para-
site line D10 immunoprecipitated with anti-protein 4.1 (lane A),
anti-ANK (lane B), anti-PfHRP1 (mAb 89) (lane C), and anti-
heat shock protein (lane D). Note that the phosphoproteins in
lanes A^C migrate very similarly. Extracts from equal amounts
of red cells were loaded in each lane.
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the spectrin based red cell membrane skeleton to the
red cell plasma membrane through interactions with
band 3 and spectrin [46]. It is comprised of an 89
kDa domain that binds to the cytoplasmic domain of
band 3, a 62 kDa spectrin-binding domain, and a 30^
55 kDa regulatory domain [36]. These red cell pro-
tein associations may be regulated by phosphoryla-
tion which generally reduces a red cell protein’s af-
¢nity for other membrane proteins [18,47^52].
Ankyrin and band 3 are substrates for membrane-
associated and cytosolic casein kinases [50,53,54].
Casein kinase phosphorylation a¡ects the interaction
of ankyrin with the cytoplasmic domain of band 3 by
decreasing the stoichiometry but not the a⁄nity of
ankyrin binding [48,52], whereas casein kinase phos-
phorylation of ankyrin decreases its binding a⁄nity
for spectrin [50,52].
The kinase responsible for phosphorylation of an-
kyrin that is associated with PfHRP1 is unknown.
We note, however, that in addition to red cell ki-
nases, a casein kinase of apparent parasite origin
has been reported [16], as has a serine^threonine ki-
nase the parasite exports to the red cell membrane
skeleton [55], although the role either of these kinases
plays in this process is yet to be determined. The
results of the present study show that the phosphor-
ylated 89 kDa band 3 binding domain of ankyrin is
associated with PfHRP1. In a previous study, we
have shown in infected red cells that expression of
PfHRP1 in£uences phosphorylation, by a casein ki-
nase, of two other membrane-associated proteins, the
parasite protein MESA, as well as the red cell mem-
brane protein 4.1 [20]. We suggest that PfHRP1, in
addition to the role it plays in knob formation and
cytoadherence [14], may have a role in pathways that
a¡ect phosphorylation of several membrane proteins
in the infected red cell.
Proteolysis also may be utilized by malarial para-
sites in the extensive restructuring of the infected red
cell membrane that occurs during the association of
PfHRP1 and other malarial proteins with red cell
skeletal proteins. There are several reports of proteo-
lytic digestion of spectrin in infected red cells [56^58].
Cleavage of ankyrin and association of the band 3
and spectrin binding domains with PfHRP1 may al-
low reorganization of cytoskeletal structures to suit
the parasite’s needs. Recently Hanspal et al. detected
a truncated 155 kDa fragment of ankyrin in soluble
cytosolic extracts of trophozoite/schizont-infected er-
ythrocytes cleaved within the regulatory domain by a
cysteine protease [59]. Additional cleavage steps
would be required to generate the smaller ankyrin
fragments we recognized in association with
PfHRP1, although the cleavage mechanism is as yet
not known.
The speci¢c binding region of PfHRP1 for the 89
kDa and the 62 kDa ankyrin fragments has been
localized to the K2A fragment that encompasses
the 5P repeat region of PfHRP1. Removal of the 5P
repeats resulted in loss of ankyrin binding, suggesting
that the repeats were the binding site. These repeats
consist of ¢ve copies of a 13^16 residue region rich in
lysine and glutamic acid [43]. This is the second bind-
ing interaction localized to this region, as it has al-
ready been demonstrated that the cytoplasmic tail of
PfEMP1 is strongly bound by this region [3]. The
binding constants involved are very similar with the
KDkin of K2A binding to ankyrin being 2.4 WM and
for PfEMP1 being 3.3 WM [3]. It is not clear whether
these two molecules compete against each other for
binding to K2A, and what the e¡ect of this might be.
This would not necessarily destabilize the PfHRPI^
PfEMPI interaction, as there are three distinct bind-
ing sites on PfHRP1 for this protein, one with a
KDkin of 0.1 WM. However, these interactions could
lead to formation of an aggregated protein complex
through the operation of multiple intermolecular as-
sociations. K2A partially overlaps the region of
PfHRPI that has been reported to bind to spectrin
[12], and recently published work shows that the cy-
toplasmic tail of PfEMP1 also binds to the spectrin^
actin junction in vitro [4], thus further emphasizing
the complex network of protein^protein interactions
formed at the knobs of the infected red blood cell.
This study presents new information about an in-
teraction between the parasite protein PfHRP1 and
erythrocyte ankyrin that would appear to play an
indirect role in anchoring PfEMP1 to the membrane
skeleton of the infected cell. It seems that PfHRP1
participates in a number of interactions that anchor
it to the membrane skeleton including those involv-
ing spectrin and actin that have been previously re-
ported [12]. The combination of these interactions is
likely to be extremely strong, thus providing a secure
base to which PfEMP1 can attach. Further, this
would allow transmission to the red cell skeleton of
BBADIS 61983 25-10-00
C. Magowan et al. / Biochimica et Biophysica Acta 1502 (2000) 461^470468
stresses experienced by PfEMP1 as it mediates adher-
ence in vivo, under £ow, in the microvasculature.
Approaches that interfere with the anchoring of
PfEMP1 to PfHRP1, or PfHRP1 to the membrane
skeleton, would weaken the ability of infected red
cells to adhere. This may have the e¡ect of amelio-
rating the severity of malaria infection, and may pro-
vide a novel chemotherapeutic approach to control-
ling this disease.
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